BioStem Technologies, Inc. (BSEM)
OTCMKTS
· Delayed Price · Currency is USD
13.54
+0.09 (0.67%)
Jun 24, 2025, 9:57 AM EDT
BioStem Technologies Revenue
BioStem Technologies had revenue of $72.53M in the quarter ending March 31, 2025, with 73.08% growth. This brings the company's revenue in the last twelve months to $332.45M, up 473.06% year-over-year. In the year 2024, BioStem Technologies had annual revenue of $301.83M with 1,708.93% growth.
Revenue (ttm)
332.45M
Revenue Growth
+473.06%
P/S Ratio
0.68
Revenue / Employee
10.07M
Employees
33
Market Cap
224.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 301.83M | 285.14M | 1,708.93% |
| Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
| Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
| Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
| Dec 31, 2017 | 313.45K | -293.78K | -48.38% |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
| Dec 31, 2011 | Pro | Pro | Pro |
| Dec 31, 2010 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
BioStem Technologies News
- 16 days ago - BioStem Technologies: Huge Growth, Poised To Help Wound Care Field - Seeking Alpha
- 4 weeks ago - Ernst & Young (EY) US Announces Jason Matuszewski, CEO of BioStem Technologies, as an Entrepreneur Of The Year® 2025 Florida Award finalist - GlobeNewsWire
- 6 weeks ago - BioStem Technologies, Inc. (BSEM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - BioStem Technologies Reports Preliminary First Quarter 2025 Operating and Financial Results - GlobeNewsWire
- 7 weeks ago - BioStem to Showcase its Leading BioREtain® Technology at the Symposium for Advanced Wound Care (SAWC) Spring Meeting - GlobeNewsWire
- 2 months ago - BioStem Technologies to Present at the Centri Capital Conference - GlobeNewsWire
- 2 months ago - BioStem Technologies, Inc. (BSEM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioStem Technologies Reports Record Preliminary Fourth-Quarter Net Revenue of $102.9 Million and Preliminary Full-Year 2024 Revenue of $301.8 Million - GlobeNewsWire